Knight Therapeutics Inc. (TSX:GUD)
Canada flag Canada · Delayed Price · Currency is CAD
9.93
+0.03 (0.30%)
Sep 10, 2026, 12:24 PM EST

Knight Therapeutics Stock Forecast

Stock Price Forecast

According to 7 analysts polled by S&P Global, Knight Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $11.19. The average 1-year stock price forecast is 12.69% higher than the current stock price, while the lowest is $10.80 (+8.76%) and the highest is $12.00 (+20.85%).

Price Target: $11.19 (+12.69%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$10.80$11.19$11.00$12.00
Change+8.76%+12.69%+10.78%+20.85%
* Price targets were last updated on Aug 7, 2026.

Analyst Ratings

The average analyst rating for Knight Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingNov '25Dec '25Feb '26Mar '26May '26Aug '26
Strong Buy322244
Buy333333
Hold111100
Sell000000
Strong Sell000000
Total766677

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Stifel Nicolaus
Stifel Nicolaus
Buy
Maintains
$9.50$11.00
BuyMaintains$9.50$11.00+10.78%Aug 7, 2026
RBC Capital
RBC Capital
Buy
Maintains
$9.50$11.00
BuyMaintains$9.50$11.00+10.78%Aug 7, 2026
Bloom Burton
Bloom Burton
Buy
Maintains
$12.00
BuyMaintains$12.00+20.85%Aug 7, 2026
Canaccord Genuity
Canaccord Genuity
Buy
Initiates
$9.50
BuyInitiates$9.50-4.33%May 8, 2026

Financial Forecast

Revenue This Year
552.38M
from 450.09M
Increased by 22.73%
Revenue Next Year
549.10M
from 552.38M
Decreased by -0.59%
EPS This Year
0.14
from 0.02
Increased by 500.86%
EPS Next Year
0.26
from 0.14
Increased by 85.71%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
243.48M293.56M328.20M371.30M450.09M552.38M
Revenue Growth
22.03%20.57%11.80%13.13%21.22%22.73%
Gross Profit
115.41M138.06M152.65M174.41M200.23M260.86M
Gross Margin
47.40%47.03%46.51%46.97%44.49%47.23%
Operating Income
-12.83M-17.06M6.37M7.40M-2.35M78.11M
Net Income
15.68M-29.89M-16.84M4.33M-5.37M13.32M
EPS
----0.020.14
EPS Growth
-----48.11%500.86%
Forward PE
82.4395.3779.24157.06201.6770.93
Free Cash Flow
-165.58M2.88M27.09M-9.70M20.39M41.20M
No. Analysts
-----7
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CAD.

Revenue Forecast

Revenue202620272028
High557.4M
Avg552.4M
Low550.0M

Revenue Growth

Revenue Growth202620272028
High
23.8%
Avg
22.7%
Low
22.2%

EPS Forecast

EPS202620272028
High0.14
Avg0.14
Low0.14

EPS Growth

EPS Growth202620272028
High
500.9%
Avg
500.9%
Low
500.9%